The Michael J. Fox Foundation Annual Report | Page 8

04

Todd Sherer, PhD

Deborah W. Brooks

Because alpha-synuclein and LRRK2 hold potential

emerged to track and measure health. The Foundation

to serve not just as drug targets but as biomarkers of

is committed to developing these technologies to

Parkinson’s disease, our landmark Parkinson’s Progression

speed Parkinson’s drug development. Patients today

Markers Initiative expanded in 2014 to build and follow

have an unprecedented opportunity to effortlessly

genetic cohorts of people who carry mutations in these

contribute immense volumes of objective data on the

genes. Study leaders also presented baseline findings at

lived experience of Park